Takeda to sell TachoSil surgical patch to Corza Health for 350m euros
Add BT as a preferred source
[TOKYO] Takeda Pharmaceutical said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros (S$563.7 million) as the Japanese company continues to divest non-core businesses.
TachoSil, a surgical patch used for bleeding control, delivered US$160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.
To reduce debt, Takeda has pledged to dispose of US$10 billion worth of non-core assets.
Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
